Clinical evaluation and mechanism study on the synergistic treatment and rehabilitation of diabetic macular edema by Chinese and Western medicine

Not Applicable

Recruiting

• Conditions: diabetic macular edema

• Registration Number: ITMCTR2022000026
• Lead Sponsor: Eye Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Synergistic Chinese and Western medicine treatment program, Synergistic Chinese and Western medicine low vision rehabilitation program.
(1) Those with poorly cleared refractive interstitium and difficulty in fundus observation.
(2) Those who have already undergone vitreous cavity injection of anti-VEGF or hormonal drugs, gridded photocoagulation, local photocoagulation, or total retinal photocoagulation within 3 months after any one or more of these treatment modalities.
(3) Those with combined fundus disease such as glaucoma, retinal vein obstruction, uveitis, or optic nerve disease.
(4) Patients with combined severe cardiovascular, hepatic and hematopoietic system diseases and diabetic nephropathy with renal failure; HBA1c = 10% and liver and kidney function test results exceeding 1.5 times normal
(5) Patients with combined serious life-threatening primary diseases and psychiatric disorders
(6) Pregnant or lactating women.
(7) Those who are participating in clinical trials of other drugs or are taking drugs that may affect the clinical evaluation of this study.
(8) Inability to cooperate during the examination and to adhere to the follow-up fundus examination.

Exclusion Criteria

Synergistic Chinese and Western medicine treatment program, Synergistic Chinese and Western medicine low vision rehabilitation program.
(1) Those with poorly cleared refractive interstitium and difficulty in fundus observation.
(2) Those who have already undergone vitreous cavity injection of anti-VEGF or hormonal drugs, gridded photocoagulation, local photocoagulation, or total retinal photocoagulation within 3 months after any one or more of these treatment modalities.
(3) Those with combined fundus disease such as glaucoma, retinal vein obstruction, uveitis, or optic nerve disease.
(4) Patients with combined severe cardiovascular, hepatic and hematopoietic system diseases and diabetic nephropathy with renal failure; HBA1c = 10% and liver and kidney function test results exceeding 1.5 times normal
(5) Patients with combined serious life-threatening primary diseases and psychiatric disorders
(6) Pregnant or lactating women.
(7) Those who are participating in clinical trials of other drugs or are taking drugs that may affect the clinical evaluation of this study.
(8) Inability to cooperate during the examination and to adhere to the follow-up fundus examination.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Macular central fovea thickness;Best corrected visual acuity;

Secondary Outcome Measures

Name	Time	Method
macular area no vascular area;Fixation stability;macular area blood flow density;TCM syndrom score; macular retinal sensitivity;